Isolation of a Human Betaretrovirus from Patients with Primary Biliary Cholangitis.

biliary epithelial cells (BEC) common insertion sites (CIS) human betaretrovirus (HBRV) mouse mammary tumor virus (MMTV) primary biliary cholangitis (PBC)

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
24 04 2022
Historique:
received: 25 03 2022
revised: 19 04 2022
accepted: 19 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

A human betaretrovirus (HBRV) has been linked with the autoimmune liver disease, primary biliary cholangitis (PBC), and various cancers, including breast cancer and lymphoma. HBRV is closely related to the mouse mammary tumor virus, and represents the only exogenous betaretrovirus characterized in humans to date. Evidence of infection in patients with PBC has been demonstrated through the identification of proviral integration sites in lymphoid tissue, the major reservoir of infection, as well as biliary epithelium, which is the site of the disease process. Accordingly, we tested the hypothesis that patients with PBC harbor a transmissible betaretrovirus by co-cultivation of PBC patients' lymph node homogenates with the HS578T breast cancer line. Because of the low level of HBRV replication, betaretrovirus producing cells were subcloned to optimize viral isolation and production. Evidence of infection was provided by electron microscopy, RT-PCR, in situ hybridization, cloning of the HBRV proviral genome and demonstration of more than 3400 integration sites. Further evidence of viral transmissibility was demonstrated by infection of biliary epithelial cells. While HBRV did not show a preference for integration proximal to specific genomic features, analyses of common insertion sites revealed evidence of integration proximal to cancer associated genes. These studies demonstrate the isolation of HBRV with features similar to mouse mammary tumor virus and confirm that patients with PBC display evidence of a transmissible viral infection.

Identifiants

pubmed: 35632628
pii: v14050886
doi: 10.3390/v14050886
pmc: PMC9146342
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : MOP115154
Pays : Canada
Organisme : CIHR
ID : MOP 114998
Pays : Canada

Références

Sci Rep. 2020 Jun 8;10(1):9239
pubmed: 32514046
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Cancer Res. 2010 May 1;70(9):3576-85
pubmed: 20388779
J Hepatol. 2011 Jun;54(6):1315-6
pubmed: 21146570
J Gen Virol. 2015 Mar;96(Pt 3):650-662
pubmed: 25491421
Semin Liver Dis. 1997 May;17(2):97-103
pubmed: 9170196
J Clin Pathol. 2006 Dec;59(12):1287-92
pubmed: 16698952
J Virol Methods. 2010 Jan;163(1):157-61
pubmed: 19781575
Tumour Biol. 2017 Jun;39(6):1010428317705754
pubmed: 28621226
Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11139-11147
pubmed: 33215431
Mob DNA. 2017 Nov 02;8:15
pubmed: 29118853
J Cell Physiol. 2017 Mar;232(3):625-634
pubmed: 27333771
J Hepatol. 2011 Oct;55(4):876-84
pubmed: 21334408
Lancet. 2015 Oct 17;386(10003):1565-75
pubmed: 26364546
Nat Genet. 2002 Sep;32(1):153-9
pubmed: 12185366
J Med Virol. 2010 May;82(6):1044-50
pubmed: 20419820
Retrovirology. 2016 Jul 04;13(1):47
pubmed: 27377064
J Oncol. 2020 Jan 27;2020:8958192
pubmed: 32411244
Oncotarget. 2015 Oct 13;6(31):30453-71
pubmed: 26421711
Nature. 1971 Feb 26;229(5287):611-4
pubmed: 4925461
Oncol Lett. 2019 Aug;18(2):1356-1364
pubmed: 31423198
Nature. 1985 Apr 18-24;314(6012):633-6
pubmed: 3990796
Cancer Res. 2005 Aug 1;65(15):6651-9
pubmed: 16061645
Infect Agent Cancer. 2017 Jan 4;12:1
pubmed: 28053656
Cancer Res. 2018 Sep 15;78(18):5259-5273
pubmed: 30042152
J Virol. 2008 Feb;82(3):1360-7
pubmed: 18032509
Microbiol Mol Biol Rev. 2008 Mar;72(1):157-96, table of contents
pubmed: 18322038
Hepatology. 2012 Oct;56(4):1409-17
pubmed: 22504852
Cancer Res. 1995 Nov 15;55(22):5173-9
pubmed: 7585568
Am J Pathol. 2011 Oct;179(4):1588-90
pubmed: 21884676
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12386-90
pubmed: 12218182
Can Liver J. 2019 Winter;2(1):31-44
pubmed: 33981960
Mol Cancer Res. 2013 Oct;11(10):1141-58
pubmed: 23928056
Retrovirology. 2007 Oct 11;4:73
pubmed: 17931409
PLoS One. 2016 Apr 20;11(4):e0154070
pubmed: 27097319
Int J Hematol. 2019 Jan;109(1):5-17
pubmed: 30145780
Aliment Pharmacol Ther. 2008 Oct 1;28(7):886-94
pubmed: 18627363
Breast Cancer Res Treat. 2011 Aug;129(1):149-55
pubmed: 21365265
PLoS One. 2019 Feb 14;14(2):e0211737
pubmed: 30763339
Infect Agent Cancer. 2014 Jun 17;9:20
pubmed: 25120582
Aging (Albany NY). 2020 Jul 31;12(16):15978-15994
pubmed: 32735554
Aliment Pharmacol Ther. 2015 Feb;41(4):393-405
pubmed: 25521721
Liver Int. 2015 Apr;35(4):1442-50
pubmed: 25302564
Lancet. 1998 May 30;351(9116):1620-4
pubmed: 9620716
Liver Int. 2009 Mar;29(3):375-83
pubmed: 19018986
Bioinformatics. 2013 Feb 15;29(4):420-7
pubmed: 23267173
Hepatology. 2004 Jan;39(1):151-6
pubmed: 14752833
JAMA Netw Open. 2020 Oct 1;3(10):e2014622
pubmed: 33017027
J Natl Cancer Inst. 1977 Jun;58(6):1795-806
pubmed: 864756
Oncotarget. 2015 Jul 30;6(21):18355-63
pubmed: 26214095
Sci Rep. 2019 Feb 7;9(1):1652
pubmed: 30733546
World J Gastroenterol. 2016 Jan 7;22(1):349-60
pubmed: 26755881
J Hepatol. 2009 Mar;50(3):548-54
pubmed: 19168254
Nucleic Acids Res. 2015 Jan;43(Database issue):D844-8
pubmed: 25190456
Aging (Albany NY). 2015 Dec;7(12):1032-49
pubmed: 26655726
J Pathol. 2006 Aug;209(4):436-44
pubmed: 16710841
Clin Breast Cancer. 2020 Jun;20(3):262-273.e7
pubmed: 32229175
Gut. 2016 Feb;65(2):321-9
pubmed: 25567117
Rev Med Virol. 2004 May-Jun;14(3):169-77
pubmed: 15124233
PLoS One. 2012;7(2):e30889
pubmed: 22363509
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9
pubmed: 12832623
Acta Oncol. 2019 Feb;58(2):135-146
pubmed: 30606073
Clin Cancer Res. 2004 Nov 1;10(21):7284-9
pubmed: 15534103
Retrovirology. 2015 May 16;12:43
pubmed: 25980759
Genes Dev. 2007 Jul 15;21(14):1767-78
pubmed: 17639082
Biomed Res Int. 2020 Jul 11;2020:7575862
pubmed: 32766313
Gut. 2001 Oct;49(4):565-76
pubmed: 11559656
Br J Cancer. 2000 Jan;82(2):446-51
pubmed: 10646903
Gut. 1994 Jul;35(7):875-8
pubmed: 8063212
BMC Bioinformatics. 2010 May 11;11:237
pubmed: 20459804
Aliment Pharmacol Ther. 2007 Aug 15;26(4):587-95
pubmed: 17661762
Cell Rep. 2013 Nov 27;5(4):886-94
pubmed: 24183673
Anticancer Drugs. 2021 Sep 1;32(8):812-821
pubmed: 34102651
Front Oncol. 2018 May 07;8:141
pubmed: 29868468
Cancer Res. 2001 Feb 15;61(4):1754-9
pubmed: 11245493
Nat Rev Cancer. 2020 Oct;20(10):555-572
pubmed: 32778778
Clin Cancer Res. 2003 Mar;9(3):1118-20
pubmed: 12631616
Cancer Res. 2004 Jun 15;64(12):4105-11
pubmed: 15205319
Oncogene. 2000 Feb 21;19(8):992-1001
pubmed: 10713682
Gastroenterology. 2004 Aug;127(2):493-501
pubmed: 15300582
Int J Oncol. 2001 May;18(5):1041-4
pubmed: 11295054
J Invest Surg. 2021 Sep;34(9):1011-1020
pubmed: 32066292
EMBO J. 1986 Jan;5(1):127-34
pubmed: 3007110
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):722-727
pubmed: 28062688
Arch Virol. 2001;146(1):171-80
pubmed: 11266212
PLoS Biol. 2004 Aug;2(8):E234
pubmed: 15314653
Oncogene. 2005 Nov 21;24(52):7656-72
pubmed: 16299527
Oncotarget. 2012 Nov;3(11):1320-34
pubmed: 23131872
PLoS Pathog. 2019 Feb 15;15(2):e1007533
pubmed: 30768644
Oncogene. 2021 Mar;40(12):2243-2257
pubmed: 33649538
J Hepatol. 2011 Jun;54(6):1312-4
pubmed: 21147183
Cancer Res. 2011 Apr 15;71(8):2988-99
pubmed: 21363912
BMC Mol Biol. 2017 Sep 7;18(1):23
pubmed: 28882106

Auteurs

Mariam Goubran (M)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Weiwei Wang (W)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Stanislav Indik (S)

Department of Virology, University of Veterinary Medicine, A-1210 Vienna, Austria.

Alexander Faschinger (A)

Department of Virology, University of Veterinary Medicine, A-1210 Vienna, Austria.

Shawn T Wasilenko (ST)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Jasper Bintner (J)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Eric J Carpenter (EJ)

Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada.

Guangzhi Zhang (G)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Paulo Nuin (P)

Department of Medical Genetics, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Georgina Macintyre (G)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Gane K-S Wong (GK)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada.
Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Andrew L Mason (AL)

Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH